Dr Reddy’s Laboratories is trading higher by 2% at Rs 1,802 after the company said it has launched Zenatane in 20 mg and 40 mg in the US following its approval by the United States Food & Drug Administration (USFDA).
“The total value of the drug sales in the US was approximately $309 million for the 12 month-ending January 2013, according to IMS Health,” Dr Reddy’s said in a statement.
Zenatane capsules will be available in boxes of 30 (three prescription packs of 10 capsules), it added.
Zenatane, used for the treatment of acne, is a therapeutically-equivalent generic version of Accutane (Isotretinoin capsules USP) in the US market.
The stock opened at Rs 1,779 and touched high of Rs 1,810 on NSE. A combined 122,787 shares have changed hands on the counter till 1034 hours on NSE and BSE.
“The total value of the drug sales in the US was approximately $309 million for the 12 month-ending January 2013, according to IMS Health,” Dr Reddy’s said in a statement.
Zenatane capsules will be available in boxes of 30 (three prescription packs of 10 capsules), it added.
Zenatane, used for the treatment of acne, is a therapeutically-equivalent generic version of Accutane (Isotretinoin capsules USP) in the US market.
The stock opened at Rs 1,779 and touched high of Rs 1,810 on NSE. A combined 122,787 shares have changed hands on the counter till 1034 hours on NSE and BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%